Search Results for: Research
Vascular Diseases and Therapeutics publishes 1-year study confirming MenaQ7® Vitamin K2 as MK-7 supplementation improves vascular health. A new one-year clinical trial has just been published showing that a daily nutritional dose of MenaQ7® Vitamin K2 as MK-7 improved vascular health, adding to the substantial body of evidence confirming MenaQ7® Vitamin K2 is clinically … Continue reading MenaQ7 1-Year Cardio Study Publishes
Vascular Diseases and Therapeutics publishes 1-year study confirming MenaQ7® Vitamin K2 as MK-7 supplementation improves vascular health.
A new one-year clinical trial has just been published showing that a daily nutritional dose of MenaQ7® Vitamin K2 as MK-7 improved vascular health, adding to the substantial body of evidence confirming MenaQ7® Vitamin K2 is clinically validated to offer cardiovascular support.
According to the authors of “Effect of Menaquinone-7 (vitamin K2) on vascular elasticity in healthy subjects: results from a one-year study”, Matrix Gla-Protein (MGP) is involved in the prevention of arterial calcification. During vitamin K-insufficiency, MGP is produced in its inactive form: dp-ucMGP. Two 3-year intervention studies in the general population have shown that increased vitamin K intake may decrease arterial stiffening, but the difference with placebo became only significant in the third year of treatment. “In the present trial the researchers investigated whether in a pre-selected group of vitamin K-insufficient subjects (men and women) an effect of vitamin K-supplementation may be demonstrated within one year,” the authors wrote.
High effect on women with poor vitamin K
Completed by the expert researchers at VitaK, the placebo-controlled randomised clinical trial was performed in 243 subjects (40-70 years old) characterized by circulating dp-ucMGP concentrations above the median of the general population. Arterial stiffness was concluded from the carotid-femoral pulse-wave velocity (cfPWV), and other vascular characteristics were measured by echotracking of the common carotid artery. Treatment was performed with either 180 µg/day of Vitamin K2 as MK-7 (as MenaQ7® from ex-NattoPharma) or placebo for one year.
In the total study group, MK-7 induced a significant decrease of both dp-ucMGP and cfPWV. The authors conclude: “High vitamin K intake decreased age-related vascular stiffening. The effects were most obvious in women with poor vitamin K status, and were statistically significant after one year of treatment.”
“This study continues to build the rock-solid argument that MenaQ7 Vitamin K2 – not K1 or other unstudied Vitamin K2 ingredients – delivers important cardiovascular support,” says Hogne Vik, ex-NattoPharma Chief Medical Officer. “In this study, the participants taking MenaQ7 maintained arterial flexibility and the stiffness did not increase, whereas placebo group became stiffer and less flexible.
Vik continues, “These results mirror what we have seen in epidemiological studies, where populations who consume a lot of dietary Vitamin K2 have healthier hearts and more flexible arteries, as well as our groundbreaking three-year study in healthy postmenopausal women. Vitamin K2 is indeed a vital cardiovascular support nutrient, and MenaQ7 is the only K2 as MK-7 clinically proven to do so.”
Reference:
Vermeer C and Vik H. Effect of Menaquinone-7 (vitamin K2) on vascular elasticity in healthy subjects: results from a one-year study. 2020 Vascul Dis Ther, 5: doi: 10.15761/VDT.1000179.
Make your Milk Powder as Proactive to Health as Your Consumers Are!
Consumers show a greater interest in functional products and ingredient claims than ever before, as they seek out products that offer a convenient health boost.
62% of consumers in Asia-Pacific identify “Overall Health” as the critical concern resulting from COVID-19.
Fortification is an opportunity for differentiation
Learn more about the most important vitamin consumers may never have heard of!
Adding vitamin K2 to milk powder ensures calcium is guided to building bone and diverted away from soft tissue
MenaQ7®️ K2 is clinically proven to support the needs of healthy bones in children.
Kids – Growing Strong Bones
Clinical research show children taking 45 mcg of MenaQ7® resulted in improved vitamin K status and stronger, denser bones. Milk powder as a delvery format represent an opportunity to mitigate deficency and to support children growing strong bones.
Supporting Bone Health in
Postmenopausal Women
Maintaining the best possible cardiovascular and bone health are two of the most critical areas allowing women to age in a healthy way.
MenaQ7® is the only Vitamin K2 clinically proven to protect bone strength and density in postmenopausal women.
MenaQ7® K2 is clinically proven to support bone and heart health in adults.
MenaQ7® K2 is clinically proven to support bone and heart health in adults.
Vitamin K2 is Key for Healthy Ageing
Being fearful for poor bone and cardiovascular health can be a hindrance for the growing population of senior citizens to engage in activities, travel, and exercise
Calcification is believed to be an unfortunate result of aging, but studies show that arterial calcification is, in fact, an actively regulated process.
MenaQ7® Vitamin K2 taken daily is not only shown to inhibit age-related arterial stiffening but improve vascular elasticity.
Knapen MHJ et al. Thrombosis and Haemostasis, 2015; 19;113(5).
The Only Clinically Proven K2 now available in milk powders!
Providing solutions to make Vitamin K2 available in a broader range of finished product dose forms is at the heart of the NattoPharma R&D team.
Vitamin K2 creates synergies for health and is the better together vitamin to supercharge other vital nutrients like vitamin D, Calcium and Omega3 to strengthen solid foundational health across all stages in life.
Adding MenaQ7® K2 to milk powders will ensure calcium is optimally trapped to the bone matrix and away from arteries where it can do harm.
Learn how K2 has Better Together Synergies with vitamin D for bone and cardiovascular health www.menaq7.com/bettertogether
You Have The Questions,
We Have The Answers
Is MenaQ7 compatible in milk powder?
MenaQ7® Vitamin K2 is now offered in a solution developed specifically for milk powder compatibility
- Stability protocol available
- No flavour or odour to interfere with the finished product
Are consumers interested in K2?
NattoPharma has educated the health supplement industry and has all the tools you need to tell the K2 story to consumers, we will show you how!
How do I know vitamin K2 will be bioavailable from dairy?
Study show drinkable yogurt fortified with MenaQ7 Vitamin K2 provided the same bioavailability as supplements.
What about safety and efficacy?
MenaQ7 is proven safe and efficacious in 20+ clinical trials.
Book a K2 Meeting in Your Calendar Today
Copyright Ⓒ 2015 MenaQ7. All Rights Reserved. MenaQ7 Vitamin K2 is a trademark of MattoPharma ASA.
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation. Heart Health ranks as one of the top 3 reasons respondents use dietary supplements. At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering … Continue reading Consumer Survey Shows Interest in Supplements for Artery Health
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation.
Heart Health ranks as one of the top 3 reasons respondents use dietary supplements.
At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering three primary questions:
1. How concerned are people with the health of their heart?
2. Do they believe that hard arteries are a problem that is associated with poor heart health?
3. How willing would they be to take a supplement to improve the health of their heart by preventing (and even reversing) the hardening of their arteries?
Key Findings: Of the 380 individuals surveyed:
• 87% currently take vitamins or supplements to improve their health.
• 25% identify themselves as having a condition associated with heart disease; 40% have someone in their immediate family with a condition associated with heart disease.
• 35% are very concerned that hardening of the arteries will have a negative impact on their heart health.
• 67% of those surveyed (n = 380) would take a supplement shown to stop hardening of the arteries if the supplement carried no side effects and is priced about the same as other heart health supplements.
Bone and Heart Health are the top reasons customers supplement (reason 2 and 3, respectively). When asked how concerned they were about their heart health on a scale of 1-7, 62% rated their level of concern as 5 or greater (38% rated their level of concern 6 or greater).
Of those who indicated that they or their family member currently has a heart condition (n=232),
• 84% are currently taking a prescription medicine (55% would consider taking a prescription)
• 44% are currently taking a supplement (59% would consider taking a supplement)
Of those who indicated that they currently do not have a heart condition (n=148), for those surveyed between 30 and 40 years old, supplements would be their No. 1 action if they developed heart disease.
“Just over one-third of survey participants ranked ‘hardening of the arteries’ as one of the top 3 risk factors associated with heart disease. This is a concern with growing awareness with Americans, but a natural solution to address this concern was not previously available,” said Eric Anderson, senior vice president of global sales and marketing with ex-NattoPharma, exclusive global supplier of MenaQ7® Vitamin K2 as MK-7. “However, our clinical trials have shown that MenaQ7 addresses 2 of the top 3 reasons that health-minded consumers supplement: MenaQ7 not only protects against age-related hardening of the arteries and regressed arterial stiffening, but it also has been shown to improve bone mineral density and strength.”
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos. Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”. Biolab … Continue reading Product Launch in Brazil
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos.
Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”.
Biolab Farmacêutica is one of the largest pharmaceutical companies in Brazil, and the No. 1 pharmaceutical company for cardiology prescriptions. More than 600 cardiologists attended the event hosted by Biolab, and NattoPharma, world leaders in Vitamin K2 research and development, had representatives on hand to explain the substantial body of science supporting MenaQ7 Vitamin K2 as MK-7, specifically the cardiovascular benefits.
“It was our pleasure to participate in the Brazilian launch of Doiska MenaQ7, and a privilege to present our clinical substantiation to more than 600 engaged cardiologists in São Paulo,” says Dr. Hogne Vik, ex-NattoPharma Chief Medical Officer, who presented alongside respected cardiologist Prof. Dr. Francisco Fonseca.
According to Flavio Zemella, Biolab Marketing Director, the symposium was very successful and physicians are excited about Doiska MenaQ7® arrival in the pharmacies, expected by beginning of August this year. “We are confident the partnership between ex-NattoPharma and Biolab will be very fruitful as we foresee the product will benefit thousands of Brazilians across the country.”
Supporting Mothers for Healthy Babies
Pregnancy is a time of extraordinary change and the WHO estimates 20-30% of pregnant women suffer from some kind of vitamin deficiency. Post-natal supplements are important for many women during this period of their lives to ensure not only their health, but their babies as well.
In particular, pregnant women are advised to increase their calcium levels to support the growing babies’ bone and teeth – and to maintain the mothers own bone mass, which is depleted during pregnancy and nursing.
Research shows that women’s bone metabolic status significantly changes over the period between pregnancy and during nursing [6], and as much as 50% of newborns are K deficient. Incorporating Vitamins K2 with D3 in post-natal supplements would benefit both mother and child through their combined optimization of calcium.
[6] Miyamoto T et al. Sci Rep. 2019 May 13;9(1):6787.
MenaQ7 study show
45 mcg per day of vitamin K2 was shown to support the needs of healthy bones in children
Growing Strong Bones
Childhood is the most essential period for developing and building healthy bone mass.
However, research shows children have 8 to 10 times higher levels of inactive osteocalcin, which means they are not optimally building the bone mass they require during this period.[3]
In turn, today we see an increase in low-energy fractures in children. Thankfully there is a way to mitigate this situation.
Studies show that children who have optimal levels of Vitamins K2 and D3 have fewer bone fractures than children with lower status of these two vitamins. [4,5]
MenaQ7® is the only Vitamin K2 on the market proven to benefit bone health in children.
[3] Theuwissen E et al. Food & Function. 2013;5(2):229-34
[4] Popko J et al. Nutrients. 2018 Jun 6;10(6):734.
[5] Karpiński M et al. J Am Coll Nutr. 2017 Jan;36(1):64-71